Oil rebounds, but gains limited amid demand concerns as India reels from COVID-19

Oil rebounds, but gains limited amid demand concerns as India reels from COVID-19

TOKYO: Oil prices rebounded on Tuesday after falling in the previous session, but gains are likely to be capped amid growing concern about fuel demand in India, the world’s third-biggest crude importer now slammed by spiralling new coronavirus cases.

Brent crude was up 36 cents, or 0.6%, at $66.01 a barrel by 0334 GMT, after dropping 0.7% on Monday. U.S. oil gained 36 cents, or 0.6%, to $62.27, having declined by 0.4% the previous session.

India’s woes comes as the Organization of the Petroleum Exporting Countries (OPEC) and allies led by Russia, a group known as OPEC+, are set to discuss policy on production at a meeting this week.

The OPEC+ joint technical committee has maintained a forecast for growth in oil demand growth this year, but has concerns about the surging COVID-19 cases in India and elsewhere, three sources from the producer group told Reuters.

“Traders are cautious ahead of the OPEC+ Ministerial meeting” this week, said Avtar Sandu, senior manager commodities at Phillip Futures in Singapore. “The OPEC technical committee acknowledged potential demand concerns about demand destruction brought about by the worsening pandemic in India.”

The Indian government ordered the country’s military to help respond to the surging coronavirus infections, with countries including Britain, Germany and the United States promising aid as the emergency overwhelms hospitals.

“The big question is whether OPEC+ feels that the situation is bad enough to alter its planned production easing from 1 May,” ING Economics analysts said in a note.

“We still expect that the group will announce no changes to its plan when they meet tomorrow.”

About Author

Related posts

Oxford Biomedica lifts outlook as AstraZeneca ramps up vaccine output

AstraZeneca (NASDAQ:AZN) UP 0.62% AT 7944 Oxford Biomedica on Tuesday doubled the revenue expectation from its COVID-19 vaccine supply deal with AstraZeneca (NASDAQ:AZN) after the drug maker commissioned more batches from the company in the second half of 2021. Shares of the cell therapy firm, which has an agreement...

Read More